Global Immunoglobulin Market 2021 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Immunoglobulin Market 2021 (Includes Business Impact of COVID-19)
Global Immunoglobulin Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global immunoglobulin market report has been segmented on the basis of mode of delivery, application, product type, and region.
Request Covid - 19 Impact
The global Immunoglobulin market size was valued at USD$ 11.83 billion in 2020 and is projected to reach UDS$21.54 billion by 2030, and is anticipated to expand at a CAGR of 6.17% over the forecast period from 2020 to 2030.


Global Immunoglobulin Market: Overview


Immunoglobulins, also known as antibodies, they are glycoprotein molecules produced by plasma cells“white blood cells. They act as a critical part of immune response system by specifically recognizing and binding to particular antigens, such as bacteria or viruses, and aiding in their destruction. Immunoglobulins occur in two main forms soluble antibodies and membrane-bound antibodies. Membrane-bound immunoglobulins are related to non-covalently with two accessory peptides, forming B-cell antigen receptor complex. The first antigen receptors expressed by B cells are IgM and IgD. The receptor is a prototype of antibody that B cell is prepared to produce.


Global Immunoglobulin Market: Dynamics


Increasing geriatric population & rising number of patients suffering from hemophilic are major factors expected to drive growth of the global immunoglobulin market. In addition, rising prevalence for chronic diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, etc., is another factor expected to boost growth of the market to certain extent.

Moreover, rapid advancements in production of immunoglobulin, owing to emergence of advanced technologies, and enhanced purification techniques is another factor expected to further support growth of the global market. In addition, increasing government expenditure on development of healthcare infrastructure, coupled with favorable reimbursement policies in developed countries are some other factors expected to further support growth of the global market.

However, stringent government regulations related to immunoglobulin products and high risk of side effects, on consumption of immunoglobulin are other factors expected to hamper growth of the global immunoglobulin market to certain extent.

Increasing investment by major players for technological advancements and R&D activities are expected to create new opportunities in terms of revenue for player operating in the global immunoglobulin market. In addition, increasing public-private partnership for innovative product offerings is expected to further support growth of the global market to certain extent.


Global Immunoglobulin Market: Region Analysis


North America is expected to dominate in the global immunoglobulin market in terms of revenue and is anticipated to continue its dominance over the forecast period. This can be attributed to well-developed healthcare infrastructure, favorable reimbursement policies, and presence of major players operating in the countries in this region. In addition, growing merger and acquisition activities among region and international players is anticipated to further support growth of the target market in this region.

The market in Asia Pacific is projected to witness faster growth, owing to increasing government expenditure on development of healthcare infrastructure, presence of prominent players operating in the emerging economies such as India and China in this region. In addition, increasing public-private partnership for R&D activities in expected to further boost growth of the target market in this region.

The market in Latin America is expected to witness moderate growth, owing to increasing presence of major pharmaceutical manufacturers in developing countries such as Brazil and Argentina in this region.


Below are the active patents related to Immunoglobulin Market.


Patent Number: CN102939111A

Process for preparing an immunoglobulin composition

Abstract

Provided is a process for the preparation of an immunoglobulin composition from a plasma comprising immunoglobulins, and antibody preparations prepared utilizing the process.

Application filed by Date: 2011-04-21

Application granted Date: 2014-10-29

Current Assignee: Biotest AG

Patent Number: US8906368B2

Immunoglobulin preparations having increased stability

Abstract

The present invention relates to a protein preparation having increased stability, comprising a stabilizer selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilizing protein preparations.

Application filed by Date: 2012-09-14

Application granted Date: 2014-12-09

Current Assignee: ZLB Bioplasma AG

Patent Number: US8920797B2

Method to produce an immunoglobulin preparation with improved yield

Abstract

The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.

Application filed by Date: 2012-10-16

Application granted Date: 2015-01-27

Current Assignee: Takeda Pharmaceutical Co Ltd

Global Immunoglobulin Market Segmentation:

By Mode of Delivery:

  
Subcutaneous
  
5% Concentration
  
20% Concentration
  
Others
  
Intravenous
  
5% Concentration
  
10% Concentration
  
Others

By Application:

  
Hypogammaglobulinemia
  
Immunodeficiency Disease
  
Multifocal Motor Neuropathy
  
Guillain-Barre Syndrome
  
Myasthenia Gravis
  
Chronic Inflammatory Demyelinating Polyneuropathy
  
Others (Idiopathic Thrombocytopenic Purpura, Specific Antibody Deficiency, and Inflammatory Myopathies)

By Product Type:

  
IgA
  
IgD
  
IgG
  
IgE
  
IgM


Key Market Players included in the report:


  
Baxter international Inc.
  
Bayer Healthcare.
  
Biotest AG
  
China Biologics Products Inc.
  
CSL Ltd.
  
Grifols S.A
  
Kedrion Biopharma Inc.
  
LFB group
  
Octapharma AG
  
Shire (Baxalta)


Below are the key development related to Immunoglobulin Market in 2020 and 2021.


March 2021: Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins. Grifols acquires the remaining 56% share capital of the U.S. biopharmaceutical company for USD 80 million. GigaGen, dedicated to the discovery and development of recombinant biotherapeutic products, is working on the worlds first recombinant polyclonal immunoglobulin. GigaGen received FDA approval of its IND application for its recombinant polyclonal anti-SARS-CoV-2 immunoglobulin. Grifols accelerates its innovation efforts to promote its strategy of long-term growth and continue executing its plan for sustained margin expansion. Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people worldwide, announced the closing of its agreement with GigaGen Inc. to acquire its remaining 56% share capital for USD 80 million. GigaGen is a U.S. biotechnology company specialized in the early discovery and development of recombinant biotherapeutic medicines. GigaGen’s research focuses on discovering new biological treatments based on antibodies derived from millions of immune system cells obtained from donors. GigaGen currently spearheads several in-house research projects, including the development of the world’s first recombinant polyclonal immunoglobulin and a portfolio of immuno-oncological therapies. Source

February 2021: Biocytogen announces acquisition of a third Beacon Optofluidic system to support expanding Antibody Discovery Platform. Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogens antibody discovery service platform in the greater Boston area for collaborations across the globe. Founded on its successful gene editing platform, Biocytogen recently developed humanized immunoglobulin mice that carry the full variable region repertoire (RenMab™), as well as a related common light chain strain, RenLite™. Generation of fully human antibodies in these models minimizes the time required to develop high-affinity antibody therapeutics with favorable pharmacokinetic properties. Biocytogens integrative use of Berkeley Lights industry-leading light-sorting technology further accelerates the process, due to the rapid screening of thousands of single B cells for antibody hit generation. Together, these technologies allow for the generation and discovery of fully human antibodies in a matter of weeks. Source

September 2020: European Medicines Agency Approves Label Update for HYQVIA® (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase), Expanding its Use to a Broader Group of Patients with Secondary Immunodeficiencies. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that the European Medicines Agency (EMA) has approved a label update for HYQVIA® (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase) broadening its use and making it the first and only facilitated subcutaneous immunoglobulin replacement therapy in adults, adolescents and children with an expanded range of secondary immunodeficiencies (SID). With the update, HYQVIA is now indicated for use as a replacement therapy in adults, children and adolescents (0-18 years) with SID who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven scientific antibody failure (PSAF) or serum IgG level of <4 g/l. Source